Pro 140

The next class of antiviral agents for the treatment of HIV

About CytoDyn

CytoDyn is committed to enhancing the lives of men and women with HIV. We focus on developing new therapies that provide flexibility and freedom to people across the globe who are living with HIV. 

Read More About CytoDyn

PRO 140

Our lead product, PRO 140, belongs to a new class of HIV/AIDS therapeutics that protects healthy cells from viral infection.  PRO 140 has several potential benefits including less frequent dosing and minimal side effects that distinguish it from currently used HIV treatments.

Read more about PRO 140

Listen to the Conference Call Replay for the Submission of Phase 3 Protocol to FDA and Upcoming Plans

A telephone replay is available until June 5, 2015.  Interested parties may dial 877-660-6853 (U.S./Canada) or 201-612-7415 (International); Conference ID: 13578723.

Shareholder's conference call update May 4, 2015

Watch how PRO 140 combats HIV Watch how PRO 140 combats HIV View Video